Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, high dose statins may unexpectedly increase cholesterol absorption from the intestine, which can limit the overall reduction in LDL-C levels, 70 increasing the risk of residual cholesterol (residual risk of major cardiovascular events).71”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Research works printed but not linked: 21
- Cholesterol Treatment Trialists' (CTT) Collaboration, 2010, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
- Roth, 2015, Circulation, 132, 1667, 10.1161/CIRCULATIONAHA.114.008720 · DOI · Paper page
- Ahn, 2015, Diabetes Metab J, 39, 87, 10.4093/dmj.2015.39.2.87 · DOI
- Rhee, 2019, Korean J Intern Med, 34, 723, 10.3904/kjim.2019.188 · DOI · Paper page
- Phan, 2012, Vasc Health Risk Manag, 8, 415
- Descamps, 2015, Atherosclerosis, 240, 482, 10.1016/j.atherosclerosis.2015.03.004 · DOI
- Kato, 2017, J Am Heart Assoc, 6, e006901, 10.1161/JAHA.117.006901 · DOI
- Saxon, 2016, Prog Cardiovasc Dis, 59, 153, 10.1016/j.pcad.2016.07.009 · DOI
- Wilson, 2019, J Am Coll Cardiol, 73, 3210, 10.1016/j.jacc.2018.11.004 · DOI · Paper page
- Wu, 2018, Endocrine, 60, 229, 10.1007/s12020-018-1541-4 · DOI
- Deushi, 2007, FEBS Lett, 581, 5664, 10.1016/j.febslet.2007.11.023 · DOI · Paper page
- Kosoglou, 2005, Clin Pharmacokinet, 44, 467, 10.2165/00003088-200544050-00002 · DOI · Paper page
- Stein, 2012, Lancet, 380, 29, 10.1016/S0140-6736(12)60771-5 · DOI · Paper page
- Reiss, 2018, Clin Sci (Lond), 132, 1135, 10.1042/CS20180190 · DOI
- Abifadel, 2003, Nat Genet, 34, 154, 10.1038/ng1161 · DOI · Paper page
- Lagace, 2014, Curr Opin Lipidol, 25, 387, 10.1097/MOL.0000000000000114 · DOI · Paper page
- Koren, 2014, Circulation, 129, 234, 10.1161/CIRCULATIONAHA.113.007012 · DOI · Paper page
- Hlatky, 2017, J Am Coll Cardiol, 70, 2677, 10.1016/j.jacc.2017.10.001 · DOI
- Kazi, 2017, JAMA, 318, 748, 10.1001/jama.2017.9924 · DOI
- Virani, 2017, Circulation, 135, 2572, 10.1161/CIRCULATIONAHA.117.028503 · DOI · Paper page
- Arrieta, 2017, JAMA Cardiol, 2, 1369, 10.1001/jamacardio.2017.3655 · DOI · Paper page
Cited by
Rakhshanda, S., Briggs, N. E., Rhee, J., Rye, K.-A., Liaw, S.-T., & Jonnagaddala, J. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag175 · Cited by 6
Metadata
- Authors
- Choi, J. Y., & Na, J. O.
- Affiliations
- Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea.
- Venue
- Journal of Lipid and Atherosclerosis
- Publisher
- XMLink
- Published
- 2019
- Volume
- 8
- Issue
- 2
- Pages
- 183
- ISSN
- 2287-2892
- 2288-2561
- Cited by
- 23
- References
- 22
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors. https://app.cochat.ai/papers/10.12997/jla.2019.8.2.183
- The paper
- Choi, J. Y., & Na, J. O. (2019). Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors. Journal of Lipid and Atherosclerosis. https://doi.org/10.12997/jla.2019.8.2.183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.